Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
A Preview Of TRACON Pharmaceuticals’s Earnings
TRACON Pharmaceuticals (NASDAQ:TCON) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement.
Analysts estimate that TRACON Pharmaceuticals will report an earnings per share (EPS) of $-0.42.
4 Stocks Under $3 Insiders Are Aggressively Buying
Gold futures traded slightly higher on Tuesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
40 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Fangdd Network Group Ltd. (NASDAQ: DUO) rose 57.1% to $0.4198 in pre-market trading.
TRACON Pharmaceuticals: Q4 Earnings Insights
TRACON Pharmaceuticals (NASDAQ:TCON) reported its Q4 earnings results on Tuesday, March 15, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Preview: TRACON Pharmaceuticals’s Earnings
TRACON Pharmaceuticals (NASDAQ:TCON) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement.
Analysts estimate that TRACON Pharmaceuticals will report an earnings per share (EPS) of $-0.35.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.